HyperSight CBCT approached simulation-CT dosimetry for offline adaptive breast radiotherapy
HyperSight reduced PTV dose-recalculation deviations versus Halcyon 3.1 while using a lower imaging dose in 12 breast radiotherapy patients.
Tag
Breast
Neoadjuvant chemotherapy shifted HR+/HER2− breast tumors toward higher genomic radioresistance
RSI increased after neoadjuvant chemotherapy in 23 of 30 matched HR+/HER2− tumors, but implications for adjuvant radiation dose remain unproven.
Modern proton breast radiotherapy offers cardiopulmonary sparing but randomized clinical benefit remains pending
Modern proton techniques reduce cardiopulmonary dose and can control skin exposure, while randomized cardiac and cancer-control endpoints remain pending.
Food insecurity predicted markedly worse survival after comprehensive breast nodal irradiation
Five-year survival was 74.9% versus 90.2% for patients living in food-insecure versus other areas despite similar cancer treatment.
Clinical-genomic models improved prediction of late breast radiotherapy toxicity
Adding SNP data increased arm-lymphedema prediction AUC from 0.78 to 0.93 in the multicenter REQUITE cohort.
Particle therapy suppressed aggressive breast cancer behavior beyond clonogenic cell killing
Protons, helium and carbon ions suppressed migration and invasion that increased after photon irradiation, with helium showing a favorable biological-dosimetric balance.
FES PET changed nodal staging, field design and boost dose in ER-positive breast cancer
In a diagnostically difficult breast cancer case, FES PET identified occult ER-positive nodal disease and materially changed radiotherapy volume and dose.
Patients with documented fatigue were less likely to complete electronic symptom surveys after breast RT
Patients with clinician-documented fatigue had 39% lower odds of completing electronic fatigue assessments, exposing an important limitation of PRO-only monitoring.
ALTJ V35Gy above 50% tripled lymphedema risk after breast radiotherapy
Irradiating more than half of the axillary-lateral thoracic junction to 35 Gy was independently associated with a threefold higher lymphedema risk.
Dose–LET hotspots were associated with capsular contracture after proton postmastectomy radiotherapy
Combined high-dose and high-LET exposure around breast implants was associated with severe capsular contracture after proton postmastectomy radiotherapy.
Higher immune-cell radiation dose was associated with worse breast cancer-specific survival
Each 1-Gy increase in estimated immune-cell dose was associated with 66% higher breast cancer mortality after multivariable adjustment.
KROG 19-09 reveals major dose variation within intended breast nodal treatment groups
Substantial physician-dependent dose variation meant treatment-group assignment did not consistently reflect the dose actually delivered to regional nodes.
Radiotherapy was not associated with longer survival in breast cancer leptomeningeal disease
In 232 women with breast cancer leptomeningeal disease, radiotherapy was not associated with longer overall survival, while systemic therapy was.
Bullous pemphigoid developed during breast radiotherapy with concurrent pembrolizumab
Bullous pemphigoid emerged after seven radiotherapy fractions during pembrolizumab, spreading beyond the treatment field and ultimately preventing completion of both therapies.
Baseline extracellular-vesicle microRNAs were associated with breast radiotherapy toxicity
Baseline miR-144-5p and miR-222-3p differed in patients who later developed greater radiation toxicity, but the signals require validation.